Compare AGO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGO | ACAD |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.3B |
| IPO Year | 2003 | 2000 |
| Metric | AGO | ACAD |
|---|---|---|
| Price | $85.36 | $24.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | ★ $101.67 | $30.55 |
| AVG Volume (30 Days) | 300.5K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | 49.34 | ★ 69.12 |
| EPS | ★ 1.91 | 0.02 |
| Revenue | ★ $1,110,000,000.00 | $726,437,000.00 |
| Revenue This Year | $3.06 | $18.80 |
| Revenue Next Year | N/A | $11.70 |
| P/E Ratio | ★ $44.08 | $1,241.50 |
| Revenue Growth | 27.29 | ★ 40.45 |
| 52 Week Low | $72.76 | $19.69 |
| 52 Week High | $92.40 | $28.35 |
| Indicator | AGO | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 51.72 |
| Support Level | $85.41 | $20.56 |
| Resistance Level | $85.82 | $25.36 |
| Average True Range (ATR) | 1.56 | 0.76 |
| MACD | 0.05 | -0.26 |
| Stochastic Oscillator | 86.40 | 23.84 |
Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.